ONE-WAYOngoing theme · still written in the latest filings

Development of F230 as a Treatment for Pulmonary Arterial Hypertension

A development program to develop F230 as a treatment for pulmonary arterial hypertension, file for and obtain IND approval in China, and then initiate a Phase 1 clinical trial.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2024-Q1 →Still being written about.

Directionhelps1 helps · 0 hurts · 0 flat